Shawn Zhi Zheng Lin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Shawn Zhi Zheng Lin has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
Jinesh Mukesh Shah
Department of Neurology, National Neuroscience Institute, Singapore
2 shared publications- Jingwei Sim
Department of Neurology National Neuroscience Institute (Tan Tock Seng Hospital Campus) Singapore Singapore
2 shared publications Marco Lizwan
Ministry of Health Holdings, Singapore, Singapore
2 shared publications- Simon Kang Seng Ting
Department of Neurology, Singapore General Hospital, Singapore, Singapore
2 shared publications Sumit Kumar Sonu
Department of Neurology, National Neuroscience Institute (Singapore General Hospital Campus), Singapore, Singapore
2 shared publications- Weishan Li
Department of Neurology, National Neuroscience Institute, Singapore
2 shared publications
Latest Publications
- 28 July 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 107 (2) , e218277
Neuropathologic Correlates of Seizures in Patients With Alzheimer Disease and Dementia With Lewy Bodies
Seizures are a recognized comorbidity in dementia, with varying prevalence across Alzheimer disease (AD) and dementia with Lewy bodies (DLBs). Although previous studies have demonstrated an increased seizure risk in AD, the neuropathologic substrates underlying seizure susceptibility-particularly across dementia subtypes-remain incompletely understood. We aimed to identify distinct clinicopathologic correlates of clinically active seizures in AD and DLB using a large autopsy-confirmed cohort. We conducted a retrospective cohort study using data from the National Alzheimer's Coordinating Center (2005-December 2022). Autopsy-confirmed AD and DLB cases were included. Individuals with a history of stroke or traumatic brain injury were excluded. The primary outcome was clinically active seizures, defined as seizures occurring within 3 years before or after the diagnosis of dementia. Neuropathologic exposures included Braak stage, cerebral amyloid angiopathy (CAA), frontotemporal lobar degeneration, and vascular pathologies. Multivariable logistic regression models were used to examine associations between pathologic features and seizure occurrence, adjusting for relevant demographic covariates. A total of 3,498 participants were included, comprising 3,040 with AD (mean age, 73.4 years; 48.5% female) and 458 with DLB (mean age, 75.1 years; 31.4% female). Active seizures were identified in 174 participants with AD (5.7%) and 13 with DLB (2.8%). In AD, Braak stage VI (vs V) was associated with higher odds of active seizures (adjusted odds ratio [OR], 1.81; 95% CI 1.20-2.82; p = 0.007), as was moderate to severe CAA (adjusted OR, 1.38; 95% CI 1.01-1.90; p = 0.045). In DLB, AD-related pathologic features were not associated with seizures. By contrast, vascular pathology was significantly associated with seizure occurrence, including microinfarcts (adjusted OR, 5.11; 95% CI 1.64-16.4; p = 0.005) and infarcts (adjusted OR, 4.11; 95% CI 1.27-12.9; p = 0.015). In this autopsy-confirmed cohort, seizure susceptibility was associated with advanced tau pathology and CAA in AD. In DLB, exploratory analyses suggested a possible association between vascular pathology and seizures; however, these findings should be interpreted cautiously. Overall, the results support potentially distinct pathologic contributions to seizure susceptibility across dementia subtypes. Limitations include the use of advanced-stage pathologic samples, which may limit generalizability to earlier disease stages.
- 28 July 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 107 (2) , e218277
Neuropathologic Correlates of Seizures in Patients With Alzheimer Disease and Dementia With Lewy Bodies
Seizures are a recognized comorbidity in dementia, with varying prevalence across Alzheimer disease (AD) and dementia with Lewy bodies (DLBs). Although previous studies have demonstrated an increased seizure risk in AD, the neuropathologic substrates underlying seizure susceptibility-particularly across dementia subtypes-remain incompletely understood. We aimed to identify distinct clinicopathologic correlates of clinically active seizures in AD and DLB using a large autopsy-confirmed cohort. We conducted a retrospective cohort study using data from the National Alzheimer's Coordinating Center (2005-December 2022). Autopsy-confirmed AD and DLB cases were included. Individuals with a history of stroke or traumatic brain injury were excluded. The primary outcome was clinically active seizures, defined as seizures occurring within 3 years before or after the diagnosis of dementia. Neuropathologic exposures included Braak stage, cerebral amyloid angiopathy (CAA), frontotemporal lobar degeneration, and vascular pathologies. Multivariable logistic regression models were used to examine associations between pathologic features and seizure occurrence, adjusting for relevant demographic covariates. A total of 3,498 participants were included, comprising 3,040 with AD (mean age, 73.4 years; 48.5% female) and 458 with DLB (mean age, 75.1 years; 31.4% female). Active seizures were identified in 174 participants with AD (5.7%) and 13 with DLB (2.8%). In AD, Braak stage VI (vs V) was associated with higher odds of active seizures (adjusted odds ratio [OR], 1.81; 95% CI 1.20-2.82; p = 0.007), as was moderate to severe CAA (adjusted OR, 1.38; 95% CI 1.01-1.90; p = 0.045). In DLB, AD-related pathologic features were not associated with seizures. By contrast, vascular pathology was significantly associated with seizure occurrence, including microinfarcts (adjusted OR, 5.11; 95% CI 1.64-16.4; p = 0.005) and infarcts (adjusted OR, 4.11; 95% CI 1.27-12.9; p = 0.015). In this autopsy-confirmed cohort, seizure susceptibility was associated with advanced tau pathology and CAA in AD. In DLB, exploratory analyses suggested a possible association between vascular pathology and seizures; however, these findings should be interpreted cautiously. Overall, the results support potentially distinct pathologic contributions to seizure susceptibility across dementia subtypes. Limitations include the use of advanced-stage pathologic samples, which may limit generalizability to earlier disease stages.
- Open Access
Automated Multisource Electronic Frailty Index in Acute Ischemic Stroke: Development and Clinical Utility
Background: Frailty is common in acute ischemic stroke (AIS) and predicts poor outcomes, but is not routinely captured in acute stroke care. Manual frailty tools are difficult to apply consistently in busy inpatient settings, while existing electronic frailty indices (eFIs) often rely on limited data modalities. We developed a scalable pre-stroke electronic frailty index (eFI) using multisource electronic medical record (EMR) data and evaluated its clinical utility. Methods: We conducted a retrospective cohort study of AIS admissions to Singapore General Hospital from July 1, 2024, to January 31, 2025. A fully automated pipeline derived an eFI from EMR data over a 3-year lookback period, incorporating ICD-10 codes, vital signs, anthropometry, laboratory results, medications, and free-text documentation processed using artificial intelligence–augmented extraction of predefined, clinically interpretable deficits. Candidate variables were screened using a validated 10-step frailty index framework and refined by multidisciplinary expert consensus. Results: Among 501 AIS cases, the pipeline generated 75 candidate variables and a final 33-variable eFI, with scores derived for 492 cases (98.2%). Frail patients had greater premorbid disability, higher stroke severity, longer hospitalization, greater rehabilitation use, worse discharge disability, higher 30-day readmission, and higher cumulative post-discharge mortality. In multivariable analyses adjusted for age, sex, NIHSS, premorbid mRS, and reperfusion therapy, each 0.1-unit increase in eFI was associated with mortality beyond 90 days after discharge (adjusted HR, 1.47; 95% CI, 1.19–1.81), 30-day readmission (adjusted OR, 1.91; 95% CI, 1.43–2.59), longer hospital stay (β, 2.8 days; 95% CI, 1.4–4.2), and discharge to inpatient rehabilitation rather than home (adjusted RRR, 1.66; 95% CI, 1.27–2.16). Conclusions: In a well-documented acute stroke service supported by comprehensive longitudinal EMR data, automated multisource eFI derivation was feasible and clinically informative in AIS, capturing baseline vulnerability beyond conventional stroke measures and supporting frailty-informed risk stratification and discharge planning.
Open AccessAutomated Multisource Electronic Frailty Index in Acute Ischemic Stroke: Development and Clinical Utility
Background: Frailty is common in acute ischemic stroke (AIS) and predicts poor outcomes, but is not routinely captured in acute stroke care. Manual frailty tools are difficult to apply consistently in busy inpatient settings, while existing electronic frailty indices (eFIs) often rely on limited data modalities. We developed a scalable pre-stroke electronic frailty index (eFI) using multisource electronic medical record (EMR) data and evaluated its clinical utility. Methods: We conducted a retrospective cohort study of AIS admissions to Singapore General Hospital from July 1, 2024, to January 31, 2025. A fully automated pipeline derived an eFI from EMR data over a 3-year lookback period, incorporating ICD-10 codes, vital signs, anthropometry, laboratory results, medications, and free-text documentation processed using artificial intelligence–augmented extraction of predefined, clinically interpretable deficits. Candidate variables were screened using a validated 10-step frailty index framework and refined by multidisciplinary expert consensus. Results: Among 501 AIS cases, the pipeline generated 75 candidate variables and a final 33-variable eFI, with scores derived for 492 cases (98.2%). Frail patients had greater premorbid disability, higher stroke severity, longer hospitalization, greater rehabilitation use, worse discharge disability, higher 30-day readmission, and higher cumulative post-discharge mortality. In multivariable analyses adjusted for age, sex, NIHSS, premorbid mRS, and reperfusion therapy, each 0.1-unit increase in eFI was associated with mortality beyond 90 days after discharge (adjusted HR, 1.47; 95% CI, 1.19–1.81), 30-day readmission (adjusted OR, 1.91; 95% CI, 1.43–2.59), longer hospital stay (β, 2.8 days; 95% CI, 1.4–4.2), and discharge to inpatient rehabilitation rather than home (adjusted RRR, 1.66; 95% CI, 1.27–2.16). Conclusions: In a well-documented acute stroke service supported by comprehensive longitudinal EMR data, automated multisource eFI derivation was feasible and clinically informative in AIS, capturing baseline vulnerability beyond conventional stroke measures and supporting frailty-informed risk stratification and discharge planning.
- Open Access
- 30 June 2026
- Published by MDPI AG in Healthcare
- Vol. 14 (13) , 1898
Transtheoretical Model (TTM)-Based, TTM-Informed and TTM-Congruent Behaviour Change Interventions for Adults with Mild Cognitive Impairment and Dementia Risk: A Scoping Review
Background/Objectives: Mild cognitive impairment (MCI) is a clinically important state associated with an increased risk of future cognitive decline and dementia. Behaviour change interventions may support risk reduction and self-management in cognitively vulnerable adults. However, the extent to which the transtheoretical model (TTM) has been used in this population has not been clearly mapped. This scoping review examined TTM-based, TTM-informed, and TTM-congruent behaviour change interventions for adults with MCI, subjective cognitive concerns, or elevated dementia risk. Methods: This scoping review followed Joanna Briggs Institute guidance and was reported in accordance with PRISMA-ScR. The protocol was prospectively registered on the Open Science Framework. PubMed, PsycINFO, ScienceDirect, Scopus, Web of Science, CENTRAL, ProQuest Dissertations, and medRxiv were searched from inception to 30 September 2025. Eligible studies included randomised, nonrandomised, quasi-experimental, and qualitative designs. Data were charted using a piloted extraction form and were synthesised narratively. Results: Eight unique studies, represented across nine publications, were included. Only one trial explicitly operationalised the TTM in a clinically defined MCI cohort; most studies were more appropriately classified as TTM-informed or TTM-congruent. Recurrent intervention components included readiness alignment, goal setting, self-monitoring, personalised feedback, prompts and cues, problem solving, reinforcement, and relational support. Behavioural outcomes were more consistently favourable than cognitive outcomes, particularly for adherence, self-management, diet, and sustained physical activity engagement. Cognitive findings were heterogeneous: some smaller studies reported short-term improvements, whereas the largest rigorous trial found no significant cognitive benefit. Conclusions: Current evidence does not support strong claims regarding TTM-specific cognitive efficacy in MCI. Instead, it suggests that TTM-informed and TTM-congruent interventions may be useful for strengthening behavioural regulation, risk reduction, and maintenance of health-related routines in cognitively vulnerable adults. More rigorous studies are needed to test the TTM constructs prospectively and to determine whether proximal behavioural change translates into durable cognitive or functional benefit.
- 30 June 2026
- Published by MDPI AG in Healthcare
- Vol. 14 (13) , 1898
Open AccessTranstheoretical Model (TTM)-Based, TTM-Informed and TTM-Congruent Behaviour Change Interventions for Adults with Mild Cognitive Impairment and Dementia Risk: A Scoping Review
Background/Objectives: Mild cognitive impairment (MCI) is a clinically important state associated with an increased risk of future cognitive decline and dementia. Behaviour change interventions may support risk reduction and self-management in cognitively vulnerable adults. However, the extent to which the transtheoretical model (TTM) has been used in this population has not been clearly mapped. This scoping review examined TTM-based, TTM-informed, and TTM-congruent behaviour change interventions for adults with MCI, subjective cognitive concerns, or elevated dementia risk. Methods: This scoping review followed Joanna Briggs Institute guidance and was reported in accordance with PRISMA-ScR. The protocol was prospectively registered on the Open Science Framework. PubMed, PsycINFO, ScienceDirect, Scopus, Web of Science, CENTRAL, ProQuest Dissertations, and medRxiv were searched from inception to 30 September 2025. Eligible studies included randomised, nonrandomised, quasi-experimental, and qualitative designs. Data were charted using a piloted extraction form and were synthesised narratively. Results: Eight unique studies, represented across nine publications, were included. Only one trial explicitly operationalised the TTM in a clinically defined MCI cohort; most studies were more appropriately classified as TTM-informed or TTM-congruent. Recurrent intervention components included readiness alignment, goal setting, self-monitoring, personalised feedback, prompts and cues, problem solving, reinforcement, and relational support. Behavioural outcomes were more consistently favourable than cognitive outcomes, particularly for adherence, self-management, diet, and sustained physical activity engagement. Cognitive findings were heterogeneous: some smaller studies reported short-term improvements, whereas the largest rigorous trial found no significant cognitive benefit. Conclusions: Current evidence does not support strong claims regarding TTM-specific cognitive efficacy in MCI. Instead, it suggests that TTM-informed and TTM-congruent interventions may be useful for strengthening behavioural regulation, risk reduction, and maintenance of health-related routines in cognitively vulnerable adults. More rigorous studies are needed to test the TTM constructs prospectively and to determine whether proximal behavioural change translates into durable cognitive or functional benefit.
- 11 March 2026
- Published by Springer Nature in Journal of Neurology
- Vol. 273 (3) , 198
Early clinical characteristics of pathologically confirmed progressive supranuclear palsy and corticobasal degeneration
Objectives Although the clinical features of progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) are well documented, their early clinical presentations from the perspective of initial clinical consultation remain less well understood. This study aimed to characterize the early clinical features of PSP and CBD to inform clinicians on diagnostic assessment and management strategies. Methods Data were obtained from the National Alzheimer’s Coordinating Center (NACC) database (2005–March 2025 data freeze). Neuropathologically confirmed cases of PSP (n = 278) and CBD (n = 149) were included. Analyses were restricted to first clinical visits, focusing on demographic, neuropsychiatric, neurological, and neuropsychological variables. Results Memory symptoms were reported in more than half of both groups, whereas language impairment was more common in CBD (> 70%) and associated with higher odds of CBD diagnosis. Depression was frequent (~ 50%), with PSP showing higher odds for depressive symptoms but lower odds for disinhibition. Although 20–30% of both PSP and CBD patients exhibited no parkinsonian signs at presentation, gait disturbance, falls, and slowness were common and strongly associated with PSP. Approximately half of both groups presented with cognitive-predominant onset, and nearly one-fifth were initially misdiagnosed as Alzheimer’s disease. Conclusions A substantial proportion of PSP and CBD patients lack parkinsonian signs at first presentation, and cognitive-onset presentations are frequent, leading to early diagnostic uncertainty. Clinicians should recognize these overlapping features when evaluating early atypical parkinsonian or cognitive syndromes.
- 11 March 2026
- Published by Springer Nature in Journal of Neurology
- Vol. 273 (3) , 198
Early clinical characteristics of pathologically confirmed progressive supranuclear palsy and corticobasal degeneration
Objectives Although the clinical features of progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) are well documented, their early clinical presentations from the perspective of initial clinical consultation remain less well understood. This study aimed to characterize the early clinical features of PSP and CBD to inform clinicians on diagnostic assessment and management strategies. Methods Data were obtained from the National Alzheimer’s Coordinating Center (NACC) database (2005–March 2025 data freeze). Neuropathologically confirmed cases of PSP (n = 278) and CBD (n = 149) were included. Analyses were restricted to first clinical visits, focusing on demographic, neuropsychiatric, neurological, and neuropsychological variables. Results Memory symptoms were reported in more than half of both groups, whereas language impairment was more common in CBD (> 70%) and associated with higher odds of CBD diagnosis. Depression was frequent (~ 50%), with PSP showing higher odds for depressive symptoms but lower odds for disinhibition. Although 20–30% of both PSP and CBD patients exhibited no parkinsonian signs at presentation, gait disturbance, falls, and slowness were common and strongly associated with PSP. Approximately half of both groups presented with cognitive-predominant onset, and nearly one-fifth were initially misdiagnosed as Alzheimer’s disease. Conclusions A substantial proportion of PSP and CBD patients lack parkinsonian signs at first presentation, and cognitive-onset presentations are frequent, leading to early diagnostic uncertainty. Clinicians should recognize these overlapping features when evaluating early atypical parkinsonian or cognitive syndromes.
- 8 August 2024
- Published by Springer Nature in Neurological Sciences
- Vol. 45 (12) , 5859-5874
Acute hemorrhagic leukoencephalitis: a case report and systematic review of factors associated with severe disability and death
Introduction Acute hemorrhagic leukoencephalitis (AHLE), a rare form of acute disseminated encephalomyelitis (ADEM), has a generally poor prognosis. However, significant variation is observed, and even complete recovery has been reported. The recent increase in the frequency of AHLE case reports is possibly contributed by the advent of COVID-19 and may have added to the heterogeneity of cases. Methods We report a fatal case of AHLE with a preceding unspecified respiratory infection, then perform a systematic review of AHLE, in an effort to delineate factors that may be associated with an ultimate outcome of severe disability (defined as modified Rankin scale score of 4 or 5) or death. Results Descriptions of 31 cases of AHLE were found in 21 identified articles, with our case being the 32nd case. The most common antecedent event was an infection (20 patients, 62.5%), with nearly half of these being COVID-19 (9 patients). The majority of patients had a subacute progression (1 to 10 days) from onset to clinical nadir. We found that an altered mental status (AMS) and a Glasgow Coma Scale (GCS) score of less than 12 were associated with a final outcome of severe disability or death. An abnormal upgoing plantar response was associated with a final outcome of death. COVID-19 and its vaccines were not associated with either outcome. Conclusion AMS, depressed GCS, and an upgoing plantar response at presentation may be associated with a poor outcome in AHLE. Our findings may serve as a springboard to much-needed research into the stratification of AHLE.
- 8 August 2024
- Published by Springer Nature in Neurological Sciences
- Vol. 45 (12) , 5859-5874
Acute hemorrhagic leukoencephalitis: a case report and systematic review of factors associated with severe disability and death
Introduction Acute hemorrhagic leukoencephalitis (AHLE), a rare form of acute disseminated encephalomyelitis (ADEM), has a generally poor prognosis. However, significant variation is observed, and even complete recovery has been reported. The recent increase in the frequency of AHLE case reports is possibly contributed by the advent of COVID-19 and may have added to the heterogeneity of cases. Methods We report a fatal case of AHLE with a preceding unspecified respiratory infection, then perform a systematic review of AHLE, in an effort to delineate factors that may be associated with an ultimate outcome of severe disability (defined as modified Rankin scale score of 4 or 5) or death. Results Descriptions of 31 cases of AHLE were found in 21 identified articles, with our case being the 32nd case. The most common antecedent event was an infection (20 patients, 62.5%), with nearly half of these being COVID-19 (9 patients). The majority of patients had a subacute progression (1 to 10 days) from onset to clinical nadir. We found that an altered mental status (AMS) and a Glasgow Coma Scale (GCS) score of less than 12 were associated with a final outcome of severe disability or death. An abnormal upgoing plantar response was associated with a final outcome of death. COVID-19 and its vaccines were not associated with either outcome. Conclusion AMS, depressed GCS, and an upgoing plantar response at presentation may be associated with a poor outcome in AHLE. Our findings may serve as a springboard to much-needed research into the stratification of AHLE.
- Open Access
- 14 May 2024
- Published by Wiley in Clinical Case Reports
- Vol. 12 (5) , e8932
Extraordinary linear non‐enhancing brainstem leptomeningeal metastasis from lung adenocarcinoma: A case report
Key Clinical Message: In patients with lung adenocarcinoma, angiogenesis‐altering drugs can alter the appearance of leptomeningeal metastasis on magnetic resonance imaging (MRI) scans. In the ventral brainstem, this can manifest as a unique, linear, non‐enhancing T2‐hyperintense signal.
- 14 May 2024
- Published by Wiley in Clinical Case Reports
- Vol. 12 (5) , e8932
Open AccessExtraordinary linear non‐enhancing brainstem leptomeningeal metastasis from lung adenocarcinoma: A case report
Key Clinical Message: In patients with lung adenocarcinoma, angiogenesis‐altering drugs can alter the appearance of leptomeningeal metastasis on magnetic resonance imaging (MRI) scans. In the ventral brainstem, this can manifest as a unique, linear, non‐enhancing T2‐hyperintense signal.
- 1 March 2024
- Published by ASEAN Neurological Association in Neurology Asia
- Vol. 29 (1) , 255-257
A case of primary Sjögren syndrome masquerading as post-COVID Bickerstaff encephalitis
- 1 March 2024
- Published by ASEAN Neurological Association in Neurology Asia
- Vol. 29 (1) , 255-257
A case of primary Sjögren syndrome masquerading as post-COVID Bickerstaff encephalitis
- Open Access
- 13 February 2024
- Published by Springer Nature in Research Square
Reversible Cerebral Vasoconstriction Syndrome after starting Medroxyprogesterone Acetate Therapy for Heavy Menstrual Bleeding, A Case Report
Introduction: We highlight an unusual side effect of medroxyprogesterone acetate (MPA) directly attributed to Reversible cerebral vasoconstriction syndrome (RCVS) in a young patient. Case Presentation: We describe the case of a 36-year-old lady with a significant history of heavy menstrual bleeding (HMB) secondary to adenomyosis presenting with new onset migranous headaches and right upper limb weakness after being started on MPA treatment two months prior. Magnetic Resonance Imaging (MRI) of the brain revealed acute infarcts in the left frontal lobe and right parieto-occipital region while Magnetic Resonance Angiography (MRA) demonstrated widespread luminal irregularities throughout the anterior and posterior circulations. After stopping the MPA, her headaches and weakness resolved and a repeat MRA two months later showed resolution of the multi-focal intracranial stenoses. The patient was diagnosed with RCVS secondary to MPA given the onset of headaches and strokes with multi-focal intracranial stenoses shortly after initiation of MPA and resolution of the clinical and radiological abnormalities after the drug was stopped. Conclusion To the best of our knowledge, this is the first case of RCVS that has been directly attributed to the use of MPA. Although the exact pathophysiology of RCVS has yet to be determined, this case might contribute to the understanding of its underlying mechanisms.
- 13 February 2024
- Published by Springer Nature in Research Square
Open AccessReversible Cerebral Vasoconstriction Syndrome after starting Medroxyprogesterone Acetate Therapy for Heavy Menstrual Bleeding, A Case Report
Introduction: We highlight an unusual side effect of medroxyprogesterone acetate (MPA) directly attributed to Reversible cerebral vasoconstriction syndrome (RCVS) in a young patient. Case Presentation: We describe the case of a 36-year-old lady with a significant history of heavy menstrual bleeding (HMB) secondary to adenomyosis presenting with new onset migranous headaches and right upper limb weakness after being started on MPA treatment two months prior. Magnetic Resonance Imaging (MRI) of the brain revealed acute infarcts in the left frontal lobe and right parieto-occipital region while Magnetic Resonance Angiography (MRA) demonstrated widespread luminal irregularities throughout the anterior and posterior circulations. After stopping the MPA, her headaches and weakness resolved and a repeat MRA two months later showed resolution of the multi-focal intracranial stenoses. The patient was diagnosed with RCVS secondary to MPA given the onset of headaches and strokes with multi-focal intracranial stenoses shortly after initiation of MPA and resolution of the clinical and radiological abnormalities after the drug was stopped. Conclusion To the best of our knowledge, this is the first case of RCVS that has been directly attributed to the use of MPA. Although the exact pathophysiology of RCVS has yet to be determined, this case might contribute to the understanding of its underlying mechanisms.